News

All the original Phytopharm patents and rights will revert to Phytopharm. In addition, Unilever has granted Phytopharm a non-exclusive, perpetual, irrevocable, worldwide, royalty-free license, with the right to

The Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, v2.0 utilizes a unique design to simultaneously amplify and detect two separate regions of the HIV-1 genome, the company said. This approach

Budesonide MMX is an oral corticosteroid currently being investigated in two multi-center Phase III clinical trials involving more than 800 patients in North America and Europe for the

Under the terms of the collaborative agreement with GlaxoSmithKline (GSK), Synta is eligible for a total of $585 million in pre-commercial milestone payments. These milestones are related to

The first study, Revive (TA-301), is a randomized, double-blind, placebo-controlled, efficacy and safety study of avanafil in men with a history of erectile dysfunction (ED). Subjects will undergo

The DM-230 study met its primary endpoint of demonstrating glycemic control as measured by a reduction of hemoglobin A1c (HbA1c) of 1.6% from 8.8% to 7.2% for subjects

The Phase II study evaluated the safety and efficacy of a daily 240mg oral dose of neratinib in 136 women diagnosed with ErbB-2-positive locally advanced or metastatic breast

On successful conclusion of this preclinical evaluation, initial clinical testing could start in 2010/11, the company said. The Parkinson’s vaccine specifically targets the alpha-synuclein (alpha-syn) protein, which is

These oral vaccines represent Barr’s first in-house biologics development initiative and demonstrate the company’s ability to develop, manufacture and conduct clinical trials for biologic products, said Barr. The